REMARKS

The amendment does not introduce new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendments before examination.

The Examiner is invited to telephone the undersigned attorney if she has any questions or comments.

Respectfully submitted,

NATH & ASSOCIATES PLLC

NATH & ASSOCIATES PLLC

1030 15th Street, N.W.

6th Floor

Washington, D.C. 20005

Tel: (202) 775-8383

Fax: (202) 775-8396

GMN:TLJ/SMM\amend.final.wpd

M. Nath

26,965 No ~ $\mathcal{L}_{\mathsf{Req}}$.

Todd L. Juneau

Reg. No. 40,669

Customer No. 20529

Appendix A ("mark-up" copy of amended claims)

- 8. (Once amended) A [pharmaceutical] composition comprising the combination product of claim 5 and further comprising a pharmaceutically acceptable diluent or carrier.
- 14. (Once amended) A [pharmaceutical] composition, comprising an antisense deoxyoligonucleotide having a sequence according to SEQ ID No. 1 or SEQ ID No. 2, and further comprising a pharmaceutically acceptable carrier or diluent.

Appendix B ("clean" copy of amended claims)

0	8. A composition comprising the combination product
C	of claim 5 and further comprising a pharmaceutically
	acceptable diluent or carrier.
12	14. A composition, comprising an antisense
	deoxyoligonucleotide having a sequence according to SEQ
	ID No. 1 or SEQ ID No. 2 , and further comprising a
	pharmaceutically acceptable carrier or diluent.